Sutent FDA Approval History
FDA Approved: Yes (First approved January 26, 2006)
Brand name: Sutent
Generic name: sunitinib malate
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Gastrointestinal Stromal Tumor, Renal Cell Carcinoma, Pancreatic Cancer
Sutent (sunitinib malate) is an oral multi-kinase inhibitor indicated for the treatment of gastrointestinal stromal tumors, advanced renal cell carcinoma (RCC), adjuvant treatment of patients at high risk of recurrent RCC following nephrectomy, and the treatment of pancreatic neuroendocrine tumors.
Development timeline for Sutent
| Date | Article |
|---|---|
| Nov 16, 2017 | Approval FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma |
| May 20, 2011 | Approval FDA Approves Sutent for Rare Type of Pancreatic Cancer |
| Jan 26, 2006 | Approval FDA Approves Sutent for Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma |
| Aug 10, 2005 | Pfizer Submits New Drug Application for Sutent to FDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
